HK1016472A1 - Activated protein c formulations. - Google Patents

Activated protein c formulations.

Info

Publication number
HK1016472A1
HK1016472A1 HK99101418A HK99101418A HK1016472A1 HK 1016472 A1 HK1016472 A1 HK 1016472A1 HK 99101418 A HK99101418 A HK 99101418A HK 99101418 A HK99101418 A HK 99101418A HK 1016472 A1 HK1016472 A1 HK 1016472A1
Authority
HK
Hong Kong
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
HK99101418A
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1016472A1 publication Critical patent/HK1016472A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK99101418A 1997-04-28 1999-04-08 Activated protein c formulations. HK1016472A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
HK1016472A1 true HK1016472A1 (en) 1999-11-05

Family

ID=21936854

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99101418A HK1016472A1 (en) 1997-04-28 1999-04-08 Activated protein c formulations.

Country Status (35)

Country Link
US (4) US6159468A (es)
EP (2) EP0875563A3 (es)
JP (2) JP4383546B2 (es)
KR (2) KR100450856B1 (es)
CN (2) CN1227025C (es)
AR (2) AR015598A1 (es)
AT (1) ATE285788T1 (es)
AU (2) AU743531B2 (es)
BR (2) BR9809304B1 (es)
CA (2) CA2288143C (es)
CO (2) CO4950523A1 (es)
CZ (1) CZ298429B6 (es)
DE (1) DE69828330T2 (es)
DK (1) DK0875252T3 (es)
EA (2) EA004881B1 (es)
EG (1) EG23685A (es)
ES (1) ES2234072T3 (es)
HK (1) HK1016472A1 (es)
HU (2) HUP0003401A3 (es)
ID (2) ID23172A (es)
IL (2) IL132325A (es)
IN (2) IN183798B (es)
MY (2) MY118591A (es)
NO (2) NO995134L (es)
NZ (2) NZ500346A (es)
PE (2) PE86299A1 (es)
PL (2) PL195642B1 (es)
PT (1) PT875252E (es)
SI (1) SI0875252T1 (es)
SV (2) SV1998000050A (es)
TR (2) TR199902529T2 (es)
TW (2) TWI242443B (es)
UA (2) UA55448C2 (es)
WO (2) WO1998048822A1 (es)
ZA (2) ZA983496B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2288143C (en) 1997-04-28 2012-08-21 Eli Lilly And Company Activated protein c formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ES2259248T3 (es) * 1998-11-13 2006-09-16 Eli Lilly And Company Uso de la proteina c humana para la preparacion de un medicamento para el tratamiento de trombocitopenia inducida por heparina.
ES2195655T3 (es) * 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
BR9915572A (pt) * 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
WO2000033867A1 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
AU2002327649A1 (en) 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
PL376219A1 (en) * 2002-10-29 2005-12-27 Alza Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
ES2386972T3 (es) * 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
EP2142565A4 (en) * 2007-03-29 2010-03-31 Abbott Lab CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
ES2905874T3 (es) * 2016-06-01 2022-04-12 Servier Ip Uk Ltd Formulaciones de óxido de polialquileno-asparaginasa y métodos para elaborar y usar las mismas
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CA2288143C (en) 1997-04-28 2012-08-21 Eli Lilly And Company Activated protein c formulations
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
DK0875252T3 (da) 2005-04-25
HU224826B1 (en) 2006-02-28
CA2287267C (en) 2006-08-15
EA004881B1 (ru) 2004-08-26
KR100450856B1 (ko) 2004-10-02
WO1998048822A1 (en) 1998-11-05
SV1998000051A (es) 1998-12-11
EG23685A (en) 2007-05-09
BR9809304B1 (pt) 2011-02-08
AU740753C (en) 2002-10-10
AU740753B2 (en) 2001-11-15
CN1261280A (zh) 2000-07-26
HUP0003401A3 (en) 2003-01-28
TR199902529T2 (xx) 2000-02-21
HUP0100284A3 (en) 2003-08-28
PL336420A1 (en) 2000-06-19
DE69828330D1 (de) 2005-02-03
CZ298429B6 (cs) 2007-10-03
EP0875563A3 (en) 2000-08-02
CN1227025C (zh) 2005-11-16
IL132325A0 (en) 2001-03-19
HUP0100284A2 (hu) 2001-06-28
TR199902631T2 (xx) 2000-01-21
JP2001524111A (ja) 2001-11-27
AU7258998A (en) 1998-11-24
PE86299A1 (es) 1999-09-17
EA199900979A1 (ru) 2000-06-26
MY118591A (en) 2004-12-31
KR100564189B1 (ko) 2006-03-27
DE69828330T2 (de) 2005-10-13
TWI242443B (en) 2005-11-01
ZA983497B (en) 1999-10-25
EP0875252B1 (en) 2004-12-29
ES2234072T3 (es) 2005-06-16
AR015598A1 (es) 2001-05-16
EP0875252A3 (en) 2000-07-26
IL132502A0 (en) 2001-03-19
KR20010020325A (ko) 2001-03-15
MY120984A (en) 2005-12-30
CA2287267A1 (en) 1998-11-05
PE84799A1 (es) 1999-09-16
AU7161898A (en) 1998-11-24
US6436397B1 (en) 2002-08-20
NO995134L (no) 1999-12-21
EA199900980A1 (ru) 2000-04-24
EP0875563A2 (en) 1998-11-04
AU743531B2 (en) 2002-01-31
US6395270B1 (en) 2002-05-28
PL195642B1 (pl) 2007-10-31
NZ500346A (en) 2001-08-31
TW585871B (en) 2004-05-01
SI0875252T1 (en) 2005-06-30
CA2288143A1 (en) 1998-11-05
NO995134D0 (no) 1999-10-21
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
AR012010A1 (es) 2000-09-13
SV1998000050A (es) 1999-01-13
IN183798B (es) 2000-04-15
ATE285788T1 (de) 2005-01-15
NO995198L (no) 1999-10-25
CZ381099A3 (cs) 2000-03-15
WO1998048818A1 (en) 1998-11-05
KR20010020242A (ko) 2001-03-15
EA002149B1 (ru) 2001-12-24
EP0875252A2 (en) 1998-11-04
BR9809304A (pt) 2000-10-17
PT875252E (pt) 2005-03-31
ZA983496B (en) 1999-10-25
US6159468A (en) 2000-12-12
CN1235638C (zh) 2006-01-11
IL132325A (en) 2005-07-25
UA73071C2 (en) 2005-06-15
PL336889A1 (en) 2000-07-17
IN187157B (es) 2002-02-16
NO995198D0 (no) 1999-10-25
NZ337828A (en) 2001-06-29
CO4940438A1 (es) 2000-07-24
CO4950523A1 (es) 2000-09-01
JP2001527543A (ja) 2001-12-25
JP4383546B2 (ja) 2009-12-16
HUP0003401A2 (hu) 2001-02-28
PL195090B1 (pl) 2007-08-31
CN1254284A (zh) 2000-05-24
US6162629A (en) 2000-12-19
ID23172A (id) 2000-03-23
BR9809292A (pt) 2000-07-04
ID22933A (id) 1999-12-16
CA2288143C (en) 2012-08-21

Similar Documents

Publication Publication Date Title
HK1016472A1 (en) Activated protein c formulations.
ZA987844B (en) Therapeutic combinations.
ZA9811849B (en) Vaccine.
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
EP1113799A4 (en) PROTEIN-BASED PREPARATION
ZA982253B (en) Therapeutic compositions.
ZA966075B (en) Protein formulation.
HK1027957A1 (en) Pharmaceutical composition.
HK1016976A1 (en) Resorcinyl-triazine.
ZA981029B (en) Pharmaceutical agents.
ZA9811504B (en) Novel pharmaceutical.
ZA9811506B (en) Novel pharmaceutical.
ZA989680B (en) Pharmaceutical composition.
ZA9811505B (en) Novel pharmaceutical.
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
EP1018551A4 (en) MEGSINE PROTEIN
ZA987392B (en) Pharmaceutical composition.
HK1017834A1 (en) Bodyshaper.
GB9715064D0 (en) Protein expression
ZA983705B (en) Pregnan-3-ol-20-ones.
GB9720784D0 (en) Protein
ZA982558B (en) Novel Pharmaceutical.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090428